Skip to Content
Merck
CN

255165

Tributylmethylammonium chloride solution

75 wt. % in H2O

Synonym(s):

Methyltributylammonium chloride solution

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
CH3N[CH3(CH2)3]3Cl
CAS Number:
56375-79-2
Molecular Weight:
235.84
NACRES:
NA.22
PubChem Substance ID:
24855292
UNSPSC Code:
12352116
MDL number:
MFCD00011847

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C13H30N.ClH/c1-5-8-11-14(4,12-9-6-2)13-10-7-3;/h5-13H2,1-4H3;1H/q+1;/p-1

SMILES string

[Cl-].CCCC[N+](C)(CCCC)CCCC

InChI key

IPILPUZVTYHGIL-UHFFFAOYSA-M

vapor pressure

7.9 mmHg ( 25 °C)

Quality Level

200

assay

77.2%

form

liquid

concentration

75 wt. % in H2O

refractive index

n20/D 1.4682

bp

152 °C

density

0.964 g/mL at 25 °C

Related Categories

General description

Tributylmethylammonium chloride (TBMAC) is a quaternary ammonium salt commonly used as a phase-transfer catalyst in various organic synthesis reactions. It can also be used in the preparation of ionic liquids.

Application

Tributylmethylammonium chloride solution is used as a phase transfer catalyst in the synthesis of ɛ-caprolactone by Baeyer-Villiger oxidation of cyclohexanone in the presence of KHSO5 as an oxidizing agent.

pictograms

Exclamation markEnvironment
GHS07,GHS09

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2

Storage Class

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type ABEK (EN14387) respirator filter

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCV5897
MKCZ0018
MKCW3870
MKCW7145
MKCT0739

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

New and efficient technique for the synthesis of ?-caprolactone using KHSO5 as an oxidising agent in the presence of a phase transfer catalyst
Baj S, et al.
Applied Catalysis A: General, 395(1-2), 49-52 (2011)
Enantioselective biocatalytic reduction of 2 H-1, 4-benzoxazines using imine reductases
Zumbra?gel N, et al.
The Journal of Organic Chemistry, 84(3), 1440-1447 (2018)
J W Smit et al.
The Journal of pharmacology and experimental therapeutics, 286(1), 321-327 (1998-07-10)
We recently showed that absence of mdr1-type P-glycoprotein (P-gp) in mice resulted in profoundly reduced hepatic and intestinal clearance of type 1 and type 2 cationic drugs compared with that in wild-type mice. These data strongly support the concept that
J W Smit et al.
British journal of pharmacology, 123(3), 361-370 (1998-03-21)
1. In the present study it was tested whether known P-glycoprotein (P-gp) substrates/MDR reversal agents interact with small (type 1) and bulky (type 2) cationic drugs at the level of biliary excretion in the rat isolated perfused liver model (IPRL).
Min-Koo Choi et al.
Journal of pharmaceutical sciences, 94(2), 317-326 (2004-12-01)
The in vivo canalicular excretion clearance of tributylmethyl ammonium (TBuMA), a P-glycoprotein (P-gp) substrate, was previously reported to be unaffected by the induction of an experimental hepatic injury (EHI) by CCl(4) despite the increased expression of P-gp in the EHI
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service